Which companies are Wanbangde Pharmaceutical's closest peers?

The cockpit's peer set: Hunan Er-Kang Pharmaceutical (300267.SZ), Guizhou Bailing Group Pharmaceutical (002424.SZ), Bide Pharmatech (688073.SS), Oric Pharmaceuticals (ORIC), Beijing Sun-Novo Pharmaceutical Research (688621.SS), Zhejiang Ausun Pharmaceutical (603229.SS), Aarti Pharmalabs (AARTIPHARM.NS), Dezhan Healthcare (000813.SZ).

How has Wanbangde Pharmaceutical stock performed?

Over six months to 6 Nov 2026 the shares returned -65.0% against -11.9% for the median peer; over one year -34.9%.

← CockpitCompetitor Analysis › 002082.SZ Wanbangde Pharmaceutical Holding Group Co., Ltd. Class AOpen in the cockpit ↗

Wanbangde Pharmaceutical Holding Group Co., Ltd. Class A002082.SZCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Major

Zhejiang pharmaceutical holding company with stakes in drug manufacturing and healthcare-related businesses.

Momentum laggard 10

Competitor Analysis ▸ Charts Open in the cockpit

Mkt cap

$909M

US dollars, full cap

Free float

98%

of shares outstanding

$/day

$17.5M

20-day average traded

Fwd P/E

n/m

no positive forecast

ROIC−WACC

-7.8 pp

WACC 6.9%

Hurdle

+38 pp

Req g minus delivered

Close · CNYCN¥9.97

1D+3.5%

1W+2.0%

1M-14.6%

3M-0.3%

6M-65.0%

YTD-28.4%

1Y-34.9%

ATR %7.3%

52w lowhigh72.5% off high

What Wanbangde Pharmaceutical does

Zhejiang pharmaceutical holding company with stakes in drug manufacturing and healthcare-related businesses.

Products and services

Pharmaceutical manufacturing subsidiaries

Where it sits in the supply chain

Pharmaceuticals
Holding company

Moat: none. Diversified holding structure with no single dominant franchise.

Headquarters: Zhejiang, China · Employees: 1,348

Wanbangde Pharmaceutical at a glance

Size Wanbangde Pharmaceutical (002082.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $909M, the 2496th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥9.97 on 6 Nov 2026.

Performance Over six months the shares fell 65.0%, against -11.9% for the median peer and -16.4% for the China market (cap-weighted) — lowest of 20 in its peer set.

Growth Revenue fell 11.2% over the last twelve months (peer median +1.3%); the operating margin is -3.3% (peer median 3.6%).

Valuation It trades at 5.9× enterprise value to sales against a peer median of 4.4× (6th most expensive of 18).

Price implies For today's price to make sense, revenue must grow about -1% a year for seven years (Req g). Recent delivered growth is -39%, so the hurdle is +38 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 7.8 points below its cost of capital (6.9% WACC).

Relative performance

Six months, rebased to 100: Wanbangde Pharmaceutical against the median of its 20 peers (local-currency closes).

Wanbangde Pharmaceutical financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
	TTM	FY2025	FY2024	FY2023	FY2022
Revenue	CN¥1.13B	CN¥1.11B	CN¥1.44B	CN¥1.53B	CN¥1.77B
Revenue growth	—	-22%	-6%	-13%	—
Gross profit	CN¥421M	CN¥317M	CN¥543M	CN¥568M	CN¥862M
EBITDA	CN¥95.4M	-CN¥23.1M	CN¥184M	CN¥169M	CN¥341M
Net income	-CN¥117M	-CN¥167M	CN¥55.4M	CN¥49.2M	CN¥93.3M
Free cash flow	CN¥479M	CN¥303M	CN¥32.3M	-CN¥199M	-CN¥406M
Capital expenditure	CN¥139M	CN¥302M	CN¥88.4M	CN¥129M	CN¥167M
Total debt	CN¥1.07B	CN¥1.17B	CN¥1.06B	CN¥1.01B	CN¥912M

Quarterly statements and history in the cockpit →

Wanbangde Pharmaceutical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

Up and to the right = strong over both horizons. Wanbangde Pharmaceutical is the large dot.

Fundamentals: revenue growth against valuation

Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Wanbangde Pharmaceutical is the large dot.

Capital: growth delivered against growth the price implies

Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Wanbangde Pharmaceutical is the large dot.

Wanbangde Pharmaceutical competitors and peer comparison

How Wanbangde Pharmaceutical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Wanbangde Pharmaceutical against its 20 peers (data as of 6 Nov 2026)
Measure	002082.SZ	Peer median	Rank in peer set
1-month return	-14.6%	-6.6%	3rd lowest of 20
6-month return	-65.0%	-11.9%	lowest of 20
Distance from 52-week high	-72.5%	-33.9%	lowest of 21
Revenue growth (TTM)	-11.2%	+1.3%	4th lowest of 19
Operating margin	-3.3%	3.6%	6th lowest of 19
EV / Sales	5.9×	4.4×	6th most expensive of 18
Growth the price implies (Req g, 7 yrs)	-1.2%	16.2%	2nd least demanding of 8
Growth delivered (Del g)	-39.5%	+12.4%	lowest of 8
Hurdle (Req g minus delivered)	+38.3 pp	-9.9 pp	most demanding of 8
ROIC minus cost of capital	-7.8 pp	-2.2 pp	4th lowest of 17
EV / EBITDA	69.7×	18.2×	most expensive of 7
Net debt / EBITDA	5.3×	1.8×	most indebted of 7

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
Company	Market	Market cap	6M return	Revenue growth	Op. margin	EV / Sales	Req g	Delivered g
Wanbangde Pharmaceutical 002082.SZ	China	$909M	-65%	-11%	-3%	5.9×	-1.2%	-39.5%
Hunan Er-Kang Pharmaceutical 300267.SZ	China	$909M	-33%	-14%	-29%	5.2×	n/a	n/a
Guizhou Bailing Group Pharmaceutical 002424.SZ	China	$907M	-12%	-25%	2%	2.9×	16.2%	-0.2%
Bide Pharmatech 688073.SS	China	$912M	+5%	+10%	19%	3.6×	16.7%	+27.7%
Oric Pharmaceuticals ORIC	United States	$914M	0%	n/a	n/a	n/a	n/a	n/a
Beijing Sun-Novo Pharmaceutical Research 688621.SS	China	$894M	-8%	-1%	-2%	6.1×	n/a	n/a
Zhejiang Ausun Pharmaceutical 603229.SS	China	$893M	-27%	+1%	0%	7.1×	n/a	n/a
Aarti Pharmalabs AARTIPHARM.NS	India	$892M	+19%	+13%	18%	4.3×	n/a	n/a
Dezhan Healthcare 000813.SZ	China	$928M	-18%	-10%	-121%	15.8×	n/a	n/a
GuangYuYuan Chinese Herbal Medicine 600771.SS	China	$930M	-24%	-6%	5%	4.4×	33.2%	+4.2%
Corvus Pharmaceuticals CRVS	United States	$887M	-32%	n/a	n/a	n/a	n/a	n/a
Nxera Pharma 4565.T	Japan	$932M	+63%	+24%	14%	5.1×	16.2%	+27.3%
Aktis Oncology AKTS	United States	$880M	-15%	+337%	-1,150%	57.5×	n/a	n/a
Hunan Warrant Pharmaceutical 688799.SS	China	$942M	-20%	+5%	9%	4.7×	n/a	n/a
City Therapeutics CTY	United States	$944M	n/a	+388%	-442%	n/a	n/a	n/a
Daewoong Pharm 069620.KS	South Korea	$874M	-30%	+9%	12%	0.7×	n/a	n/a
Pharming PHARM.AS	Netherlands	$874M	-2%	+2%	9%	2.1×	2.5%	+12.4%
Northeast Pharmaceutical 000597.SZ	China	$948M	-10%	-6%	3%	1.0×	-6.8%	-0.7%
Immatics IMTX	United States	$952M	-44%	-65%	-556%	10.7×	n/a	n/a
Hygeia Healthcare 6078.HK	Hong Kong	$861M	-7%	+2%	14%	1.9×	4.8%	+22.5%
Kaken Pharmaceutical 4521.T	Japan	$854M	-8%	-7%	11%	0.9×	n/a	n/a

Questions

Which companies are Wanbangde Pharmaceutical's closest peers?: The cockpit's peer set: Hunan Er-Kang Pharmaceutical (300267.SZ), Guizhou Bailing Group Pharmaceutical (002424.SZ), Bide Pharmatech (688073.SS), Oric Pharmaceuticals (ORIC), Beijing Sun-Novo Pharmaceutical Research (688621.SS), Zhejiang Ausun Pharmaceutical (603229.SS), Aarti Pharmalabs (AARTIPHARM.NS), Dezhan Healthcare (000813.SZ).
Is Wanbangde Pharmaceutical expensive compared with its peers?: On ev / sales it trades at 5.9× against a peer median of 4.4×, 6th most expensive of 18 in its peer set. For today's price to make sense, revenue must grow about -1% a year for seven years (Req g). Recent delivered growth is -39%, so the hurdle is +38 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Wanbangde Pharmaceutical stock performed?: Over six months to 6 Nov 2026 the shares returned -65.0% against -11.9% for the median peer; over one year -34.9%.